Dysbiosis and structural disruption of the respiratory microbiota in COVID-19 patients with severe and fatal outcomes.
Adolescent
Adult
Aged
Bacteria
/ genetics
COVID-19
/ microbiology
Case-Control Studies
Dysbiosis
/ microbiology
Female
Humans
Kaplan-Meier Estimate
Male
Microbiota
/ genetics
Middle Aged
Phylogeny
RNA, Ribosomal, 16S
/ genetics
Respiratory System
/ microbiology
SARS-CoV-2
/ genetics
Severity of Illness Index
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 10 2021
29 10 2021
Historique:
received:
18
05
2021
accepted:
18
10
2021
entrez:
30
10
2021
pubmed:
31
10
2021
medline:
16
11
2021
Statut:
epublish
Résumé
The COVID-19 outbreak has caused over three million deaths worldwide. Understanding the pathology of the disease and the factors that drive severe and fatal clinical outcomes is of special relevance. Studying the role of the respiratory microbiota in COVID-19 is especially important as the respiratory microbiota is known to interact with the host immune system, contributing to clinical outcomes in chronic and acute respiratory diseases. Here, we characterized the microbiota in the respiratory tract of patients with mild, severe, or fatal COVID-19, and compared it to healthy controls and patients with non-COVID-19-pneumonia. We comparatively studied the microbial composition, diversity, and microbiota structure between the study groups and correlated the results with clinical data. We found differences in the microbial composition for COVID-19 patients, healthy controls, and non-COVID-19 pneumonia controls. In particular, we detected a high number of potentially opportunistic pathogens associated with severe and fatal levels of the disease. Also, we found higher levels of dysbiosis in the respiratory microbiota of patients with COVID-19 compared to the healthy controls. In addition, we detected differences in diversity structure between the microbiota of patients with mild, severe, and fatal COVID-19, as well as the presence of specific bacteria that correlated with clinical variables associated with increased risk of mortality. In summary, our results demonstrate that increased dysbiosis of the respiratory tract microbiota in patients with COVID-19 along with a continuous loss of microbial complexity structure found in mild to fatal COVID-19 cases may potentially alter clinical outcomes in patients. Taken together, our findings identify the respiratory microbiota as a factor potentially associated with the severity of COVID-19.
Identifiants
pubmed: 34716394
doi: 10.1038/s41598-021-00851-0
pii: 10.1038/s41598-021-00851-0
pmc: PMC8556282
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
21297Subventions
Organisme : Consejo Nacional de Ciencia y Tecnología
ID : CVU: 1095665
Organisme : Consejo Nacional de Ciencia y Tecnología
ID : "Caracterización de la diversidad viral y bacteriana"
Informations de copyright
© 2021. The Author(s).
Références
Hum Microb J. 2020 Aug;17:100073
pubmed: 32835135
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Immunology. 2017 Aug;151(4):363-374
pubmed: 28542929
Biol Proced Online. 2021 Jun 1;23(1):10
pubmed: 34058978
Signal Transduct Target Ther. 2021 May 13;6(1):191
pubmed: 33986253
Cell Discov. 2021 Apr 13;7(1):23
pubmed: 33850111
Microorganisms. 2020 Dec 28;9(1):
pubmed: 33379162
Tohoku J Exp Med. 2020;250(4):271-278
pubmed: 32321874
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
Nucleic Acids Res. 2013 Jan 7;41(1):e1
pubmed: 22933715
Intensive Care Med. 2021 Mar;47(3):292-306
pubmed: 33559707
J Genet Genomics. 2021 Sep 20;48(9):803-814
pubmed: 34238684
Cell Rep. 2019 Jul 2;28(1):245-256.e4
pubmed: 31269444
Nucleic Acids Res. 2002 Jul 15;30(14):3059-66
pubmed: 12136088
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Proc Natl Acad Sci U S A. 2008 Aug 12;105 Suppl 1:11512-9
pubmed: 18695234
NPJ Biofilms Microbiomes. 2021 Jul 22;7(1):61
pubmed: 34294722
Int J Environ Res Public Health. 2021 Feb 23;18(4):
pubmed: 33672177
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
New Microbes New Infect. 2014 Jul;2(4):106-14
pubmed: 25356355
Physiology (Bethesda). 2020 Sep 1;35(5):288-301
pubmed: 32783610
F1000Res. 2016 Jun 27;5:1519
pubmed: 27853510
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
Commun Biol. 2021 Feb 18;4(1):240
pubmed: 33603076
Nat Rev Microbiol. 2017 May;15(5):259-270
pubmed: 28316330
Lancet Respir Med. 2019 Oct;7(10):907-920
pubmed: 30975495
ISME J. 2012 Mar;6(3):610-8
pubmed: 22134646
Cell Host Microbe. 2015 May 13;17(5):704-15
pubmed: 25865368
Int J Infect Dis. 2016 Jul;48:33-9
pubmed: 27155209
Front Microbiol. 2020 Jul 31;11:1840
pubmed: 32849438
Thorax. 2009 Oct;64 Suppl 3:iii1-55
pubmed: 19783532
Respir Res. 2019 Dec 3;20(1):272
pubmed: 31796027
Eur Respir J. 2017 Dec 14;50(6):
pubmed: 29242257
Microbiome. 2021 Jun 8;9(1):132
pubmed: 34103074
J Allergy Clin Immunol. 2021 Apr;147(4):1226-1233.e2
pubmed: 33577896
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Med Hypotheses. 2020 Nov;144:110209
pubmed: 33254516
Nat Immunol. 2019 Oct;20(10):1279-1290
pubmed: 31501577
Cell. 2012 Jun 22;149(7):1578-93
pubmed: 22726443
Ann Am Thorac Soc. 2016 Dec;13 Suppl 2:S462-S465
pubmed: 28005424
Mucosal Immunol. 2017 Mar;10(2):299-306
pubmed: 27966551
Front Microbiol. 2021 Jun 23;12:687513
pubmed: 34248910
PLoS One. 2010 Mar 10;5(3):e9490
pubmed: 20224823
Front Microbiol. 2021 Jul 30;12:671813
pubmed: 34394024
Gastroenterology. 2020 Sep;159(3):944-955.e8
pubmed: 32442562
ACS Nano. 2020 May 26;14(5):5179-5182
pubmed: 32356654
Clin Infect Dis. 2020 Dec 17;71(10):2669-2678
pubmed: 32497191
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Microbiome. 2018 May 17;6(1):90
pubmed: 29773078
Gut. 2021 Apr;70(4):698-706
pubmed: 33431578
Acta Pharm Sin B. 2020 Feb;10(2):249-261
pubmed: 32082971
Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16892-16898
pubmed: 31391302
iScience. 2020 Apr 24;23(4):101007
pubmed: 32305861
Cell. 2017 Feb 23;168(5):928-943.e11
pubmed: 28215708
Clin Infect Dis. 2021 Aug 2;73(3):376-385
pubmed: 32463434
Nucleic Acids Res. 2017 Jul 3;45(W1):W180-W188
pubmed: 28449106
BMJ Open. 2021 Jan 11;11(1):e044640
pubmed: 33431495
Nat Rev Cardiol. 2020 May;17(5):259-260
pubmed: 32139904